Skip to main content
Erschienen in: BMC Cancer 1/2024

Open Access 01.12.2024 | Research

Epidemiology, characteristics, and prognostic factors of lymphoplasmacyte-rich meningioma: a systematic literature review

verfasst von: Xiaoxi Zhu, Yanhua Liu, Weiwei Guo, Qi Liang, Chengliang Pan, Bin Tan, Ying Yu

Erschienen in: BMC Cancer | Ausgabe 1/2024

Abstract

Backgrounds

Lymphoplasmacyte-rich meningioma(LPM) is a rare subtype of meningioma with a low degree of malignancy and an overall preferable prognosis. The purpose of this article is to increase the understanding of the disease, reduce misdiagnosis, and improve prognosis.

Methods

A search was conducted in the PubMed database for English articles published from 1993 to 2023. The keywords were "lymphoplasmacyte-rich (all fields) and meningioma (all fields) and English (lang)" and "lymphoplasmacyte-rich meningioma (title/abstract) and English (lang)".We further analyzed the clinical manifestations, imaging manifestations, pathological features, treatment strategies, and prognosis of LPM.The possible prognostic indicators were analyzed by the log-rank test and Pearson’s chi-squared test.

Results

Fourteen reports with 95 LPM patients were included in this report, including 47 males and 48 females who were diagnosed between the ages of 9 and 79, with an average age of 45 years. The most common clinical manifestations are headache and limb movement disorders. In most cases, the tumor occurred on the convex portion of the brain. All tumors showed significant enhancement, with homogeneous enhancement being more common, and most patients showed peritumoral edema. Postoperative pathological EMA, LCA, and vimentin positivity were helpful for the final diagnosis of the patient. Log-rank tests showed a correlation between complete resection and better prognosis and recurrence.

Conclusion

There is a lack of significant differences in the clinical symptoms and imaging manifestations of LPM compared to other diseases that need to be differentiated, and a clear diagnosis requires pathological examination. After standardized surgical treatment, the recurrence rate and mortality rate of LPM are both low. Complete surgical resection of tumors is associated with a better prognosis and lower recurrence rate.
Hinweise

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Introduction

Meningiomas are the most common primary tumor in the central nervous system (CNS), with a slow growth rate. In the latest 2021 World Health Organization (WHO) classification of central nervous system tumors, meningiomas are classified into 3 levels and a total of 15 subtypes, with grade 1 meningiomas being the most common in clinical practice [1]. The earliest report on LPM was in 1971 [2], and it was first included in the WHO classification in 1993. LPM belongs to a rare histological subtype of Grade 1 meningiomas, characterized by inflammatory cells with extensive infiltration and different proportions of meningioma cells, and infiltrating lymph plasma cells can even cover up the composition of meningeal epithelial cells [1]. The incidence rate of LPM is less than 1% [3] in meningiomas. Although LPM has been included in the WHO classification for 30 years, there are few cases report on LPM, with most of them being isolated cases report except for a few studies.The number of reported cases is too small to identify the clinical features that can help to definitively differentiate these meningiomas from typical meningiomas. The clinical, radiologic and pathologic features, and differential diagnosis of LPMs remain unclear.It is difficult to differentiate LPM from idiopathic hypertrophic pachymeningitis (IHP), inflammatory pseudotumor, Rosette-Doffmann disease and other diseases before surgery.Although it is clear that LPM is characterized by marked lymphoplasmacytic infiltration that often masks inconspicuous meningoepithelial components, its origin, whether neoplastic or inflammatory, remains controversial.In addition, factors associated with prognosis after surgical resection need to be further studied. In this article, we conducted a systematic review based on PubMed and analyzed the clinical manifestations, radiological manifestations, treatment strategies, pathological feature statistics and prognosis to help clinicians better understand this rare condition.Meanwhile, this paper discusses some characteristic manifestations of LPM such as edema and hematological abnormalities to have a positive effect on further study of this disease.

Materials and methods

In this study, all patients were clearly diagnosed with LPM according to the WHO classification criteria for central nervous system tumors. We searched for articles related to LPM in the PubMed database. We reviewed the English literature published from 1993 to May 2023. The key words are "lymphoplasmacyte-rich (all fields) and meningioma (all fields) and English (lang)" and "lymphoplasmacyte-rich meningioma (title/abstract) and English (lang)". The inclusion criteria were as follows: (i) published in English, (ii) complete radiological examination results, (iii) confirmed as LPM through pathological examination, and (iv) treatment strategies, including subtotal resection and total resection.

Article selection

A total of 55 related articles were retrieved, of which in 32 articles,patients were clearly diagnosed with LPM. According to our inclusion criteria, a total of 14 articles met our inclusion/exclusion criteria(Fig. 1). A total of 95 LPM patients were confirmed by postoperative pathological results, met all inclusion criteria and were included in the final analysis.To determine the validity of the selected articles, Zhu and Liu evaluated the data integrity of the case reports. If there were differences, the article was reviewed and discussed again until a consensus was reached. If the number of patients, diagnosis age, clinical symptoms, tumor location, imaging manifestations, treatment methods, and intervention types are mostly clearly described, the effectiveness of the case report is considered "good".

Data statistics and analysis

We further analyzed its clinical manifestations, tumor location, radiological manifestations, pathological features, treatment strategies, and prognosis. The relapse-free survival (RFS) period was defined as the time from tumor resection to tumor relapse on imaging. Single-factor analysis using log-rank tests was used to evaluate intergroup differences and identify factors associated with recurrence in LPM patients. A p value of ≤ 0.05 was considered statistically significant.

Results

Epidemiological statistics

In all 95 patients, the ratio of males to females was approximately 1 (47:48). The age at diagnosis was 9–79 years old, with an average age of 45 years. Most of the patients were diagnosed at 30–50 years old. In addition to the 56 patients with an unspecified age by Tao et al., the age at diagnosis in the remaining 39 patients was 45.4 ± 15.7 years old(Fig. 2).At the time of diagnosis, the most common symptoms of patients were headache, limb weakness, dizziness, blurred vision, numbness and seizures. Seven patients were diagnosed with a general medical examination. Tumors were mainly located in the convex part of the brain (48 cases) and lateral ventricles (6 cases). Twenty-eight patients had tumors located at the skull base, mainly distributed in the sphenoid ridge (9 cases), foramen magnum (6 cases), and tuberculum sellae (5 cases). A total of 34 patients had blood test results, of whom 9 patients showed hematological abnormalities and anemia. In T1-weighted imaging, 73 lesions were isointense or hypointense, and 1 lesion was hyperintense. On T2-weighted imaging, 9 lesions were hypointense, and 65 lesions were isointense or hyperintense. All 89 patients with enhanced MRI information showed enhancement, with homogeneous enhancement being the main manifestation (55 cases). Additionally, 19 patients showed heterogeneous enhancement, and in 15 patients, the enhancement status was not clearly indicated. Thirty-four patients underwent head CT examination, of whom 17 showed high-density lesions, 11 showed isodense lesions, and 6 showed mixed-density lesions. Tumor size was reported in a total of 63 patients, with 31 patients having a tumor length diameter less than 45 mm and 32 patients having a tumor length diameter greater than 45 mm. Fifty-one patients showed peritumoral edema (51/65), while 14 patients showed no significant peritumoral edema (14/65). A summary of the patient data is shown in Table 1,and Table 2 summarizes the demographics and clinical characteristics of these patients in detail.
Table 1
The summary of patient data
Variables
Number
%
Gender
95
 
 Male
47
49.5%
 Fmale
48
50.5%
Age at diagnosis(years)
95
 
  < 45
47
49.5%
  >  = 45
48
50.5%
Mean
9–79
 
 Hematology
34
 
  Yes
9
26.5%
  No
25
73.5%
 Tumor size (mm)
63
 
   < 45
31
49.2%
   >  = 45
32
50.8%
 T1-weighted
74
 
  Iso-/Hypointense
73
98.6%
  Hyperintense
1
1.4%
 T2-weighted
74
 
  Hypointense
9
12.2%
  Iso-/Hyperintense
65
87.8%
 Enhancement
89
 
  Homogeneous
55
61.8%
  Heterogeneous
19
21.3%
  Yes
15
16.9%
 CT
34
 
  Hyperintense
17
50.0%
  Isodense
11
32.4%
  Mixed density
6
17.6%
 Edema
83
 
  Yes
61
73.5%
  No
22
26.5%
 EMA
63
 
   + 
62
98.4%
  -
1
1.6%
 PR
6
 
   + 
3
50.0%
  -
3
50.0%
 CD3
20
 
   + 
19
95.0%
  -
1
5.0%
 CD20
20
 
   + 
19
95.0%
  -
1
5.0%
 CD138
7
 
   + 
7
100.0%
  -
0
0.0%
 CD38
24
 
   + 
23
95.8%
  -
1
4.3%
 LCA
46
 
   + 
46
100.0%
  -
0
0.0%
 Vimentin
51
 
   + 
50
98.0%
  -
1
2.0%
 S-100
14
 
   + 
11
78.6%
  -
3
27.3%
 Ki67 + (%)
16
 
   < 5
10
62.5%
  5–10
4
25.0%
   > 10
1
6.3%
  NA
1
6.3%
 GFAP
13
 
   + 
3
23.1%
  -
10
76.9%
 Surgery
95
 
  GTR
75
78.9%
  STR
20
26.7%
 Radiotherapy
80
 
  Yes
10
12.5%
  No
70
87.5%
 Recurrence
93
 
  Yes
7
7.5%
  No
86
92.5%
NA Not available
Table 2
The detail demographic and clinical characteristics of these patients
Study
Year
Nb
Location
Age
(years)
Gender
Cliencal symptoms
History
(months)
Peripheral blood abnormalities
Maximum diameter (mm)
T1-weight
T2-weight
Enhancement
CT
Edema*
Wang,Y.B., et al. [25]
2018
1
1
Left frontal lobe
51
F
Left frontal scalp swelling
12
NA
35
Hypointense
Hyperintense
Yes
NA
NA
Yongjun, L., et al. [6]
2015
9
1
Right frontal lobe
39
F
Headache, dizziness, and vomiting(8/9)
NA
Anemia(4/9)
NA
Hypointense (9/9)
Hyperintense(7/9)
Yes(9/9)
Hyperdense(6/6)
Yes(5/6)
2
Right lateral lobe
30
M
Epilepsy(3/9)
    
Hypointense (2/9)
   
3
Occipital sagittal sinus side
52
M
Vision loss(2/9)
        
4
Cerebellopontine angle
63
F
Hearing loss(1/9)
        
5
Cerebral falx
9
F
         
6
Sphenoid ridge
47
M
         
7
Right occiput
34
M
         
8
Left forehead
59
M
         
9
Left frontal temporalis lobe
54
F
         
Tao, X., et al. [11] (multicenter study without individual information)
2017
56
56
Frontal convexity (19)
44.6 ± 12
F(28/56)
Headache or increased intracranial hypertension (24/56)
Average 2
NA
46 ± 16.7
Isointense (34/55)
Isointense (25/55)
Homogeneous enhancement (39/55)
Isodense (11/25)
- (13/56)
   
Parietal convexity (10)
 
M(28/56)
Limb weakness (8/56)
   
Hypointense (21/55)
Hypointense (5/55)
Heterogeneous enhancement (16/55)
Hyperintense (10/25)
 + (21/56)
   
Lateral ventricle (3)
  
Dizziness(7/56)
    
Hyperintense (25/55)
 
Mixed density (4/25)
 +  + (8/56)
   
Pineal region(2)
  
Blurred vision (7/56)
       
 +  +  + (14/56)
   
Posterior fossa convexity (1)
  
Numbness (6/56)
        
   
Fourth ventricle(1)
  
Seizures (6/56)
        
   
Sphenoid ridge(6)
  
Memory loss (3/56)
        
   
Tuberculum sellae/Parasellar (5)
  
Diplopia(3/56)
        
   
Cerebellopontine angle (3)
  
Facial paralysis (3/56)
        
   
Petroclival region (3)
  
Hearing loss(2/56)
        
   
Foramen magnum (2)
  
Hyposmia (3/56)
        
   
Anterior skull base (1)
  
Asymptomatic(7/56)
        
de Almeida, G.B. and G. Januário [26]
2022
1
1
Bilateral frontoparietal lobe
57
F
Left hemiparesis
NA
Normal
70
Isointense
Hypointense
Homogeneous enhancement
Hyperdense
Yes
Wang, H., et al. [7]
2021
1
1
Skull base to C6
44
M
Complaints of limb weakness
NA
Anemia
NA
Isointense
Isointense
Homogeneous enhancement
NA
NA
Gu, K.C., et al. [27]
2020
1
1
Right frontal lobe
36
M
Headache
NA
Normal
40
Hyperintense
Hypointense
Yes
Mixed density
Yes
Study
Year
Nb
Location
Age
(years)
Gender
Cliencal symptoms
History
(months)
Peripheral blood abnormalities
Maximum diameter (mm)
TIW1
T2W2
Enhancement
CT
Edema
Li, J., et al. [28]
2021
1
1
Skull base, tentorium, sella area, and C1-6
44
M
Extremities weakness
2
NA
NA
Isointense
Isointense
Homogeneous enhancement
NA
NA
Wang, Y.B., et al. [4]
2014
1
1
Ventricle
37
F
Generalized tonic–clonic seizure
5 Hours
NA
40
Hypointense
Hyperintense
Yes
NA
Yes
Kanno, H., et al. [15]
2011
1
1
Right jugular foramen
55
F
Hoarseness and dysphasia
NA
NA
15
Isointense
Hyperintense
Yes
Mixed density,
homogeneous enhancement
NA
Yang, X., et al. [29]
2018
1
1
Lateral ventricle
47
F
Occipital-cervical region pain
6
NA
NA
Isointense
Hyperintense
Yes
NA
NA
Avninder, S., V. Gupta, and K.C. Sharma [30]
2008
1
1
The medulla and upper cervical cord mass
22
F
Headache
6
NA
35
Isointense
NA
Homogeneous enhancement
NA
NA
Majumdar, K., et al. [31]
2013
1
1
Right sphenoid rigid
50
M
Blurred vision
NA
Normal
50
NA
Hyperintense
Yes
NA
NA
Zhu, H.D., et al. [8]
2013
19
1
Left occipital lobe
20
F
NA
NA
Normal
 
NA
NA
Homogeneous enhancement (11/14)
 
 + 
  
2
Right frontoparietal lobe
28
F
  
Hyperglobulinemia/Anemia
   
Heterogeneous enhancement (3/14)
 
 +  +  + 
  
3
Left temporal lobe
42
M
  
Normal
     
-
  
4
Left frontotemporal lobe
48
F
  
Normal
     
NA
  
5
Right frontal falx
77
M
  
Normal
     
-
  
6
Right frontal lobe
46
M
  
Normal
     
 + 
  
7
Left occipital lobe
46
M
  
Normal
     
-
  
8
Right frontoparietal lobe
57
M
  
Normal
     
 + 
  
9
Left sphenoid ridge
58
F
  
Normal
     
 +  + 
  
10
Right frontal falx
79
M
  
Normal
     
-
  
11
Right frontal falx
63
F
  
Normal
     
 + 
  
12
Right frontal falx
71
M
  
Normal
     
 +  + 
  
13
Right frontal lobe
46
F
  
Normal
     
 +  + 
  
14
C1-2
25
M
  
Anemia
     
-
  
15
Foramen magnum to C1-4
57
F
  
Normal
     
-
  
16
Left cerebellum &tentorium
21
F
  
Anemia
     
-
  
17
Right frontoparietal lobe
40
F
  
Normal
     
 + 
  
18
C3-4
51
M
  
Normal
     
-
  
19
Left frontoparietal lobe
24
F
  
Normal
     
 +  +  + 
Fukui, K., et al. [32]
2021
1
1
C2-3
43
M
Neck pain
12
Hyperglobulinemia/Anemia
 
Isointense
Hyperintense
Homogeneous enhancement
 
NA
*-, no edema; + , equal to or smaller than the tumor size; +  + , surpassing the tumor size; +  +  + , nearly hemispheric edema

Pathological characteristics and treatment methods

Immunohistochemical examination showed that most patients (62/63) were positive for epithelial membrane antigen (EMA), and 50/51 patients were positive for Vimentin. A total of 3/6 patients were positive for progesterone receptor(PR), 19/20 patients were positive for CD3, 19/20 patients were positive for CD20, 23/24 patients were positive for CD38, 7/7 patients were positive for CD138, 46/46 patients were positive for leukocyte common antigen (LCA), 11/14 patients were positive for S-100 protein, and 3/12 patients were positive for glial fibrillary acidic protein (GFAP). The vast majority of the patients had a Ki-67 labeling index less than 10% (14/16), with 10 cases being less than 5% and 4 cases being 5%-10%. The index size was not clearly indicated in one Ki67-positive patient. All patients underwent surgical treatment, with 2 patients receiving surgical treatment again after recurrence. Twenty patients underwent subtotal resection(STR) (20/95), and 75 patients underwent gross total resection(GTR) (75/95). Table 3 summarizes the pathological characteristics and treatment methods of these patients.
Table 3
The pathological features, therapy and follow-up of these patients
Study
Year
Nb
Pathology
Surgery
Following-up time(months)
Recurrence
0utcome
Radiotherapy
EMA
CD3
CD20
CD138
CD38
LCA
Vimentin
S100
Ki67 + (%)
GFAP
PR
Wang,Y.B., et al. [25]
2018
1
1
 + 
 + 
 + 
 + 
    
3
 
-
GTR
24
No
ANT
NA
Yongjun, L., et al. [6]
2015
9
1
 + (9/9)
   
 + (9/9)
 + (9/9)
 + (9/9)
    
GTR
42
No
ANT
No(9/9)
  
2
           
GTR
34
No
ANT
 
  
3
           
STR
56
Yes(1 year)
ANT
 
  
4
           
GTR
23
No
ANT
 
  
5
           
GTR
34
No
ANT
 
  
6
           
STR
38
No
AWT
 
  
7
           
GTR
52
No
ANT
 
  
8
           
GTR
22
No
ANT
 
  
9
           
GTR
31
No
ANT
 
Tao, X., et al. [11](multicenter study without individual information)
2017
56
56
 + (23/24)
 + (13/14)
 + (12/12)
 
 + (13/14)
 + (12/12)
 + (18/19)
 + (10/12)
1–5(5/9)
3
 
GTR (45/56)
5–97
(average41.5)
3/56(at 36 months)
Died (1/56)
Yes(6/56)
   
-(1/24)
-(1/14)
  
-(1/14)
 
-(1/19)
-(2/12)
5–10(3/9)
5
 
STR (11/56)
5/56(at 60 months)
ANT at 36 months (52/56)
No(50/56)
           
 > 10(1/9)
     
ANT at 60 months (50/56)
 
de Almeida, G.B. and G. Januário [26]
2022
1
1
 + 
 + 
 + 
        
GTR
12
No
ANT
NA
Wang, H., et al. [7]
2021
1
1
 + 
 + 
 + 
 + 
 
 + 
  
 < 1
-
 + 
STR
  
Dead 2 weeks after operation for pneumonia
No
Gu, K.C., et al. [27]
2020
1
1
 + 
 + 
 + 
 + 
 + 
 + 
 + 
-
 < 5
-
-
GTR
36
No
ANT
No
Li, J., et al. [28]
2021
1
1
 + 
 + 
 + 
 + 
 
 + 
   
-
 + 
STR
3
No
AWT
No
Wang, Y.B., et al. [4]
2014
1
1
 + 
 + 
 + 
 + 
  
 + 
 
 + 
-
-
GTR
3
No
ANT
NA
Kanno, H., et al. [15]
2011
1
1
 + 
  
 + 
 
 + 
    
 + 
GTR
9
No
ANT
NA
Yang, X., et al. [29]
2018
1
1
 + 
  
 + 
       
STR
3
No
AWT
Yes
Avninder, S., V. Gupta, and K.C. Sharma [30]
2008
1
1
 + 
    
 + 
     
GTR
12
No
ANT
NA
Majumdar, K., et al. [31]
2013
1
1
 + 
 
 + 
  
 + 
 + 
 + 
   
GTR
9
No
ANT
NA
Zhu, H.D., et al. [8]
2013
19
1
 + (19/19)
    
 + (19/19)
 + (19/19)
  
-(most)
 
GTR
Lost follow-up
  
Yes(3/19)
  
2
           
GTR
63
No
ANT
No(16/19)
  
3
           
STR
59
No
AWT
 
  
4
           
GTR
Lost follow-up
   
  
5
           
GTR
50
No
ANT
 
  
6
           
GTR
50
No
ANT
 
  
7
           
GTR
50
No
ANT
 
  
8
           
GTR
49
No
ANT
 
  
9
           
STR
46
No
AWT
 
  
10
           
GTR
45
No
ANT
 
  
11
           
GTR
41
No
ANT
 
  
12
           
GTR
39
No
ANT
 
  
13
           
GTR
39
No
ANT
 
  
14
           
GTR
37
No
ANT
 
  
15
           
STR
33
No
AWT
 
  
16
           
GTR
32
No
ANT
 
  
17
           
GTR
31
No
ANT
 
  
18
           
GTR
28
No
ANT
 
  
19
           
GTR
24
No
ANT
 
Fukui, K., et al. [32]
2021
1
1
 + 
     
 + 
 
5
-
 
STR
12
Yes(at 12 months)
AWT
NA

Follow-up, prognosis, and data analysis

The follow-up period was 3–97 months. During the follow-up period, 6 patients experienced local recurrence (6/94), and 1 patient died during the study period. Except for one patient who died of pneumonia two weeks after surgery and 2 patients lost to follow-up, the 3-year recurrence rate and 5-year recurrence rate were 5.4% (5/92) and 7.6% (7/92), respectively.A Kaplan–Meier curve was created to show the recurrence rate (Fig. 3). Two patients underwent surgical treatment again after recurrence but did not experience recurrence after the second surgery. Only one patient died of tumor recurrence within 5 years. The follow-up and prognosis of these patients are shown in Table 3. Single-factor analysis shows that peripheral blood abnormalities and whether they are completely removed are related factors that affect the improvement of postoperative symptoms in patients. Tumors that are completely removed have a relatively better prognosis. The surgical strategy also affects postoperative recurrence in patients, and patients who have undergone complete resection are less likely to experience recurrence after surgery.The results obtained from the log-rank test are presented in Table 4. The main factors affecting the surgical strategies are the tumor size and the site of tumor. Complete resection is most likely to be achieved in tumors with a size less than 45 mm and a growth site located outside the skull base.The results obtained from the Pearson’s chi-squared test are presented in Table 5. A total of 80 patients underwent postoperative radiation therapy, of whom 10 received postoperative radiation therapy. The main reason for receiving radiation therapy was that the surgery did not achieve complete resection. Although there is a report that tumors that have not been completely removed decrease in size after postoperative radiotherapy [4], statistical analysis suggests that postoperative radiotherapy has no significant correlation with prognosis or recurrence.
Table 4
The results of the log-rank test
Variable
p-value
Age(< 45)(n = 36)
  < 45
0.814
  ≥ 45
Gender(n = 36)
 Male
0.164
 Fmale
Extent of resection(n = 36)
 GTR
0.003
 STR
Location(skull base or not)(n = 36)
 No skull base
0.528
 Skull base
Peripheral blood abnormalities(n = 21)
 Normal
0.046
 Abnormal
Table 5
The results of the Pearson’s chi-squared test
Variable
GTR
STR
p-value
Age(n = 75)
  < 45
31
6
0.286
  ≥ 45
28
10
 
Tumor size (mm)(n = 63)
  < 45
29
2
0.023
  ≥ 45
23
9
 
Location(skull base or not)(n = 75)
 No skull base
43
6
0.008
 Skull base
16
10
 
Peritumoral edema(n = 58)
 Yes
30
6
0.568
 No
17
5
 
T2-weighted imaging signals(n = 64)
 Iso-/Hyperintense
45
12
0.650
 Hypointense
5
2
 

Discussion

Meningiomas are the most common benign tumor in the brain, originating from arachnoid cap cells covering the brain and spinal cord. LPM is a rare WHO I meningioma subtype with a low prevalence of meningeal epithelial tumors and a high infiltration of inflammatory cells. The majority of patients with this type of meningioma are young to middle-aged. In our study, the patients' onset ages ranged from 9–79 years old, and there was no discernible sex difference. The number of males and females was basically the same (47 vs. 48), which is consistent with previous research results and shows differences from other types of meningiomas.The incidence rates for meningiomas globally seem to be more than twice as higher in women than in men. This type of tumor mainly occurs in the convex surface and can also be seen sporadically in the spinal canal and ventricles. It is commonly solitary, but there are also individual cases of sporadic or diffuse lesions. More than 1/4 of the patients with clearly recorded hematology examination results showed hematology abnormalities, which is where LPM is significantly different from other types of meningiomas. More than 70% of patients exhibit peritumoral brain edema, and approximately one-third of patients exhibit moderate to severe edema. Although only approximately 80% of patients have GTR and the vast majority of patients have not received postoperative radiotherapy or chemotherapy, the recurrence and mortality rates of this type of tumor are extremely low.
Depending on the tumor's location and biological function, LPM patients exhibit a variety of clinical manifestations. Headaches are the most typical clinical symptom of LPM sufferers. Other commom clinical symptoms include limb weakness, seizure, dizziness, blurred vision, etc. Additionally, in a small number of patients, the tumors were found on their general medical examination without overt clinical symptoms. The natural history of LPM usually exceeds 3 months, and a few patients may have a sudden onset due to the location of the lesion or infiltration and edema of inflammatory cells. Wang et al. reported a patient with a 5-h generalized tetanic spasm as the main manifestation [5]. The differences in these symptoms may be mainly related to the location of the tumor and the compression of brain tissue by the tumor itself and surrounding edema [6].
In our study, 78.5% (51/65) of patients showed the phenomenon of peritumoral edema. Tao et al. detailed peritumoral edema in their study, of which 76.8% (43/56) of patients showed significant peritumoral edema, and among the patients with peritumoral edema, more than half of the patients showed peritumoral edema exceeding the tumor size, and even 1/3 of the patients exhibited edema nearly hemispheric [4].In our studies, we were unable to accurately assess the volume of peritumoral edema or its relationship to tumor volume, as many case reports only provided a textual description or partial imaging data on the presence or absence of edema. The occurrence of edema in meningioma is not rare, and studies have shown that peritumoral cerebral edema occurs in approximately 37% to 68% of patients with intracranial meningioma other than the suprasellar area [33]. There are multiple explanations for the mechanism of this edema. First, due to the lack of tumoral blood supply, meningiomas secrete angiogenic factors (such as VEGF-A, endothelin-1, and caveolin-1), which can lead to increased permeability of tumoral vessels and development of the peritumoral pial vascular network, ultimately leading to alterations in the extracellular matrix and plasma protein leakage [3438]. Second, large meningioma leads to brain compression, which leads to brain tissue ischemia and cytotoxic edema [33, 39]. However, the theory has obvious flaws, sometimes very small meningiomas cause extensive peritumoral edema. Other mechanisms of peritumoral edema include tumoral obstruction of veins [40] and sinuses and specific histological types of meningioma that produce eosinophilic and PAS positive inclusions and induce peritumoral edema through the osmotic mechanism [41, 42]. Osawa et al. classified meningothelial, transitional, and fibrous meningiomas as ‘WHO grade I common type’ and the other subtypes of grade I as ‘WHO grade I uncommon type’ [43]. They reported that the uncommon type had higher edema indices than the common type (69% vs. 34%). Recently, Park et al. found that IL-6 protein localized in the cytoplasm of the tumor cells, and was detected in 75% of edematous meningiomas, indicating that IL-6 expression may contribute to the formation of brain edema in meningiomas [44]. We hypothesize that massive infiltration of lymphocytes and plasma cells may play a central role in the development of the cerebral edema associated with LPM. Extensive edema may also hurt outcomes, although this was not validated in the analysis in this article. Edema brain tissue is more fragile than normal tissue, which increases the difficulty for surgeons to perform surgical procedures and further leads to the possibility of tiny residues that can serve as a basis for tumor recurrence; At the same time, the increased blood supply provided by the hyperplasia of vascular tissue in edematous brain tissue will also provide some aspect of the promotion of postoperative recurrence [45].
According to the literature, LPM is usually accompanied by abnormal peripheral blood. This special phenomenon has only been reported in two meningioma subtypes, LPM (WHO grade I) and choroid-like meningioma (WHO grade II) [2]. Abnormalities in the peripheral blood in LPM patients usually manifest as hyperglobulinemia and/or small cell hypochromic anemia [7, 8], which can usually return to normal after tumor resection.Hematologic abnormalities are not significantly related to the treatment and prognosis of LPM. Horten et al. [46]examined 5 cases considered meningiomas with extensive plasma cell-lymphocytic infiltrates. However, in the first of the 5 cases and another study by Gi et al. [47], only hypergammaglobulinemia with increased IgG was detected. The hypergammaglobulinemia is noteworthy, as it may reflect the possibility of localized neoplastic or nonneoplastic plasma cell dyscrasia or an immunoproliferative disorder at the meningeal site. Weidenheimet et al. [48] hypothesized that lymphoplasmacytic infiltration is an immune response to tumor antigenicity, while Gregorios et al. [49] hypothesized that these cells differentiate from totipotent mesenchymal cell clusters, as is the case with chronic and ongoing inflammation surrounding neoplastic meningeal epithelial components.Although hematologic bnormalities were identified in this study, the discussion of hematologic abnormalities can deepen our understanding of the pathogenesis of LPM. Kepes et al. [50] reported that choroid meningiomas are more likely to be accompanied by LPM and causes Castleman’s syndrome in children and young adults (delayed somatic and sexual development, hepatosplenomegaly, iron refractory hypochromic microcystic anemia, and bone marrow plasmacytosis with dysgammaglobulinemia). Thus we speculate that the particular histological manifestation and high proportion of dysgammaglobulinemia and/or iron refractory hypochromic microcysticanemia in LPM patients may imply similar pathogenesis of these two variants.In our study, there were 34 patients with clearly recorded haematology examination results, and more than 1/4 of the patients showed hematology abnormalities. This peripheral blood abnormalities may be secondary to the unusual immune response of the disease [9]. In this article,hematologic abnormalities may also mean a worse prognosis. It has been more than 40 years since LPM was included in the WHO classification, but the mechanism of massive infiltration of lymphocytes, plasma cells, and macrophages in this meningioma tissue remains unclear. More clinical case collection, analysis, and research may be able to provide a clear cause of this phenomenon, further suggest the origin of this type of meningioma, and provide guidance for its diagnosis and treatment.
The typical manifestations of LPM on MRI are hypointensity on T1-weighted images and hyperintensity on T2-weighted images. After enhancement, it shows homogeneous enhancement, often with obvious peritumoral brain edema and dural tail signals. The results are basically consistent with previous studie, while approximately 12.1% (9/74) of patients still exhibited hypointense T2-weighted images. All patients showed significant enhancement, but a considerable number of patients exhibited heterogeneous enhancement (19/89). The CT examination results of the patients did not show significant specificity, with half of the patients (17/34) exhibiting high-density shadows and approximately one-third of the patients still exhibiting isodense shadows. The cystic changes and heterogeneous enhancement in MRI manifestations increase the difficulty of preoperative diagnosis. Image enhancement is a helpful step to better identify the lesional tissues with lesions. Both of the tissue structures and pathological changes should be more visible after enhancement. Thus, the illuminance improvement for such images should be accounted for as well [51, 52].It would be of great interest to obtain the more typical imaging features of the LPM through the postprocessing of the images, which will help to guide diagnosis and preoperative planning.Studies have shown that in cardiovascular and retinal imaging, nonuniform contrast showed some effect [51, 53].Research has shown that most meningiomas with slow growth rates, especially those classified as WHO grade I, exhibit only moderate increases in glucose metabolism, making the detection results of 18F-flurodeoxyglucose(18F-FDG) PET unreliable [10]. Meningiomas often take up 18F-FDG at a similar or slightly lower rate than healthy grey matter. However, there has been a report of a case where the 18F-FDG uptake ratio (tumor/contralateral cortex) of the LPM was relatively high [11], at 1.38. The uptake of 18F-FDG may also increase due to inflammation, infection or granuloma. This feature is consistent with the inflammatory characteristics of LPM, but its clinical value needs further evaluation.
Pathological evaluation is the gold standard. It has been reported that EMA and vimentin staining can help to indicate the origin of the meningeal epithelium [7, 12] of tumors and distinguish LPM from other intracranial lesions, such as IHP, choroid meningioma, inflammatory pseudotumor and sinus histiocytosis with massive lymphadenopathy (SHML). In our study, tumor cells showed strong immunoreactivity to EMA and vimentin in the inflammatory background and diffuse infiltration of plasma cells and lymphocytes, which are typical LPM manifestations.
Considering that many intracranial masses may show characteristics similar to LPM, differential diagnoses should be considered, including IHP, choroid meningitis, inflammatory pseudotumor, and SHML. The pathological manifestations of IHP frequently include fibrosis and thickening of the dura mater, obvious infiltration of lymphocytes and plasma cells, and occasionally meningeal epithelial hyperplasia, which are similar to those of LPM [1315]. Because IHP typically exhibits diffuse layered thickening or patchy features, the presence of local nodular changes can usually rule out this diagnosis [16]. Choroid meningiomas usually contain areas that are histologically similar to chordomas, eosinophils with cords or trabeculae, and a rich myxoid matrix background. Histological examination can assist in differential diagnosis [17]. Inflammatory pseudotumors should also be considered an important differential diagnosis because their clinical and imaging characteristics are similar to those of LPM. Inflammatory pseudotumor is a unique solid disease that is common in the lung or other organs. It is characterized by infiltration of different numbers of muscle fibroblast spindle cells and lymphoid plasma cells [1820]. Among the reported primary intracranial inflammatory pseudotumors, meningeal lesions are the most common, even though their overall incidence rate is still low, making them rare [2123]. When plasma cell granuloma forms a meningeal mass, it is possible to make a clear histological differentiation from LPM only when there is no meningeal epithelial component in the former [24]. The typical histopathological features of SHML are an obviously dilated sinus node, fully mature histiocytes, lymphocyte phagocytosis and plasma cell proliferation. Lymphoid plasma cell-rich meningiomas in the meninges and SHML have similar radiological features and pathological manifestations [25].
The follow-up data of patients show that the recurrence and mortality rates of LPM are very low, and patients are expected to achieve long-term survival after surgery. In our study, factors related to postoperative symptom improvement in patients mainly included whether the tumor was completely removed and whether the patient had peripheral blood abnormalities. Patients with GTR and those without peripheral blood abnormalities are more likely to achieve symptom relief. Further analysis of patient data suggests that the size of the tumor, as well as whether the tumor is located at the skull base, is closely related to the surgical treatment. Patients with a tumor length < 45 mm and nonskull base locations are more likely to achieve GTR.
There are still many difficulties in achieving a preoperative diagnosis of LPM through imaging, and an accurate diagnosis of LPM requires a comprehensive analysis of imaging and pathological results. Surgical resection is still the main treatment method, and the clinical outcomes of most patients are relatively good. For patients suspected of LPM, complete tumor resection should be achieved as much as possible while ensuring patient safety. There is no clear evidence to support the positive significance of postoperative radiotherapy and chemotherapy for the prognosis of the disease. Due to the pathogenesis of the disease, hormone or immunosuppressive drug treatment may be helpful, but further observation is still needed.

Conclusion

LPM is a rare subtype of WHO grade I meningioma with low malignancy. After standardized surgical treatment, the recurrence rate and mortality rate are both low. It is difficult to make an accurate diagnosis before surgery solely based on clinical manifestations and imaging manifestations. Diagnosis requires surgical resection of the patient's tumor and completion of a pathological examination. According to our existing data, complete surgical resection of tumors is associated with a better prognosis and a lower recurrence rate.In tumors with smaller volumes and those located in nonskull bases, complete resection is more easily achieved. However, due to the small study cohort, the above conclusions are not entirely reliable. We should be aware that further larger cohort studies are needed to explore prognosis and recurrence.

Declarations

Not applicable.
Not applicable.

Competing interests

The authors declare no competing interests.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Literatur
2.
Zurück zum Zitat Banerjee AK, Blackwood W. A subfrontal tumour with the features of plasmocytoma and meningioma. Acta Neuropathol. 1971;18(1):84–8.PubMedCrossRef Banerjee AK, Blackwood W. A subfrontal tumour with the features of plasmocytoma and meningioma. Acta Neuropathol. 1971;18(1):84–8.PubMedCrossRef
3.
Zurück zum Zitat Moradi A, et al. Pathodiagnostic parameters for meningioma grading. J Clin Neurosci. 2008;15(12):1370–5.PubMedCrossRef Moradi A, et al. Pathodiagnostic parameters for meningioma grading. J Clin Neurosci. 2008;15(12):1370–5.PubMedCrossRef
4.
Zurück zum Zitat Wang YB, et al. Intraventricular lymphoplasmacyte-rich meningioma: a case report. Turk Neurosurg. 2014;24(6):958–62.PubMed Wang YB, et al. Intraventricular lymphoplasmacyte-rich meningioma: a case report. Turk Neurosurg. 2014;24(6):958–62.PubMed
5.
Zurück zum Zitat Liu JL, et al. An analysis of the magnetic resonance imaging and pathology of intracal lymphoplasmacyte-rich meningioma. Eur J Radiol. 2012;81(5):968–73.PubMedCrossRef Liu JL, et al. An analysis of the magnetic resonance imaging and pathology of intracal lymphoplasmacyte-rich meningioma. Eur J Radiol. 2012;81(5):968–73.PubMedCrossRef
6.
Zurück zum Zitat Yongjun L, et al. Imaging findings and clinical features of intracal lymphoplasmacyte-rich meningioma. J Craniofac Surg. 2015;26(2):e132–7.PubMedCrossRef Yongjun L, et al. Imaging findings and clinical features of intracal lymphoplasmacyte-rich meningioma. J Craniofac Surg. 2015;26(2):e132–7.PubMedCrossRef
7.
Zurück zum Zitat Wang H, et al. Lymphoplasmacyte-rich meningioma in the central nervous system: An unusual case report. Medicine (Baltimore). 2021;100(52):e27991.PubMedCrossRef Wang H, et al. Lymphoplasmacyte-rich meningioma in the central nervous system: An unusual case report. Medicine (Baltimore). 2021;100(52):e27991.PubMedCrossRef
8.
Zurück zum Zitat Zhu HD, et al. Lymphoplasmacyte-rich meningioma: our experience with 19 cases and a systematic literature review. Int J Clin Exp Med. 2013;6(7):504–15.PubMedPubMedCentral Zhu HD, et al. Lymphoplasmacyte-rich meningioma: our experience with 19 cases and a systematic literature review. Int J Clin Exp Med. 2013;6(7):504–15.PubMedPubMedCentral
10.
Zurück zum Zitat Nohara H, et al. Lymphoplasmacyte-rich meningioma with atypical invasive nature. Neurol Med Chir (Tokyo). 2007;47(1):32–5.PubMedCrossRef Nohara H, et al. Lymphoplasmacyte-rich meningioma with atypical invasive nature. Neurol Med Chir (Tokyo). 2007;47(1):32–5.PubMedCrossRef
11.
Zurück zum Zitat Tao X, et al. Clinical, Radiologic, and Pathologic Features of 56 Cases of Intracranial Lymphoplasmacyte-Rich Meningioma. World Neurosurg. 2017;106:152–64.PubMedCrossRef Tao X, et al. Clinical, Radiologic, and Pathologic Features of 56 Cases of Intracranial Lymphoplasmacyte-Rich Meningioma. World Neurosurg. 2017;106:152–64.PubMedCrossRef
12.
Zurück zum Zitat Hosler MR, et al. Idiopathic hypertrophic pachymeningitis mimicking lymphoplasmacyte-rich meningioma. J Neuroophthalmol. 2007;27(2):95–8.PubMedCrossRef Hosler MR, et al. Idiopathic hypertrophic pachymeningitis mimicking lymphoplasmacyte-rich meningioma. J Neuroophthalmol. 2007;27(2):95–8.PubMedCrossRef
13.
Zurück zum Zitat Nambirajan A, et al. Large dural-based mass with bony hyperostosis in a 16-year-old male: IgG4-related disease mimicking lymphoplasmacyte-rich meningioma. Childs Nerv Syst. 2019;35(8):1423–7.PubMedCrossRef Nambirajan A, et al. Large dural-based mass with bony hyperostosis in a 16-year-old male: IgG4-related disease mimicking lymphoplasmacyte-rich meningioma. Childs Nerv Syst. 2019;35(8):1423–7.PubMedCrossRef
14.
Zurück zum Zitat Tanboon J, et al. Probable IgG4-related pachymeningitis: a case with transverse sinus obliteration. Clin Neuropathol. 2013;32(4):291–7.PubMedCrossRef Tanboon J, et al. Probable IgG4-related pachymeningitis: a case with transverse sinus obliteration. Clin Neuropathol. 2013;32(4):291–7.PubMedCrossRef
15.
Zurück zum Zitat Kanno H, et al. A case of lymphoplasmacyte-rich meningioma of the jugular foramen. Brain Tumor Pathol. 2011;28(4):341–5.PubMedCrossRef Kanno H, et al. A case of lymphoplasmacyte-rich meningioma of the jugular foramen. Brain Tumor Pathol. 2011;28(4):341–5.PubMedCrossRef
16.
Zurück zum Zitat Jie D, et al. Clinical features, radiological findings, and prognostic factors for primary intracranial chordoid meningioma. Front Neurol. 2022;13:1002088.PubMedPubMedCentralCrossRef Jie D, et al. Clinical features, radiological findings, and prognostic factors for primary intracranial chordoid meningioma. Front Neurol. 2022;13:1002088.PubMedPubMedCentralCrossRef
17.
Zurück zum Zitat Patnana M, et al. Inflammatory pseudotumor: the great mimicker. AJR Am J Roentgenol. 2012;198(3):W217–27.PubMedCrossRef Patnana M, et al. Inflammatory pseudotumor: the great mimicker. AJR Am J Roentgenol. 2012;198(3):W217–27.PubMedCrossRef
18.
Zurück zum Zitat Schlimper C, et al. Radiologic features of inflammatory pseudotumors. Rofo. 2005;177(11):1506–12.PubMedCrossRef Schlimper C, et al. Radiologic features of inflammatory pseudotumors. Rofo. 2005;177(11):1506–12.PubMedCrossRef
20.
Zurück zum Zitat Häusler M, et al. Inflammatory pseudotumors of the central nervous system: report of 3 cases and a literature review. Hum Pathol. 2003;34(3):253–62.PubMedCrossRef Häusler M, et al. Inflammatory pseudotumors of the central nervous system: report of 3 cases and a literature review. Hum Pathol. 2003;34(3):253–62.PubMedCrossRef
21.
Zurück zum Zitat Suri V, et al. Intracranial inflammatory pseudotumor: report of a rare case. Neuropathology. 2008;28(4):444–7.PubMedCrossRef Suri V, et al. Intracranial inflammatory pseudotumor: report of a rare case. Neuropathology. 2008;28(4):444–7.PubMedCrossRef
22.
Zurück zum Zitat Aizawa T, et al. Intramedullary plasma cell granuloma in the cervicothoracic spine. Case report J Neurosurg. 2002;97(2 Suppl):235–8.PubMed Aizawa T, et al. Intramedullary plasma cell granuloma in the cervicothoracic spine. Case report J Neurosurg. 2002;97(2 Suppl):235–8.PubMed
23.
Zurück zum Zitat Lui PC, et al. Inflammatory pseudotumors of the central nervous system. Hum Pathol. 2009;40(11):1611–7.PubMedCrossRef Lui PC, et al. Inflammatory pseudotumors of the central nervous system. Hum Pathol. 2009;40(11):1611–7.PubMedCrossRef
24.
Zurück zum Zitat Kitai R, et al. Meningeal sinus histiocytosis mimicking lymphoplasmacyte-rich meningioma. Case report J Neurosurg. 1996;84(6):1051–4.PubMed Kitai R, et al. Meningeal sinus histiocytosis mimicking lymphoplasmacyte-rich meningioma. Case report J Neurosurg. 1996;84(6):1051–4.PubMed
25.
Zurück zum Zitat Wang Y, et al. Primary Intraosseous Lymphoplasmacyte-Rich Meningioma. World Neurosurg. 2018;109:291–3.PubMedCrossRef Wang Y, et al. Primary Intraosseous Lymphoplasmacyte-Rich Meningioma. World Neurosurg. 2018;109:291–3.PubMedCrossRef
26.
Zurück zum Zitat de Almeida GB, Januário G. Lymphoplasmacyte-rich meningioma: A rare histologic variant of benign meningioma with atypical bone invasion. Radiol Case Rep. 2022;17(3):922–7.PubMedPubMedCentralCrossRef de Almeida GB, Januário G. Lymphoplasmacyte-rich meningioma: A rare histologic variant of benign meningioma with atypical bone invasion. Radiol Case Rep. 2022;17(3):922–7.PubMedPubMedCentralCrossRef
27.
29.
Zurück zum Zitat Yang X, et al. Lymphoplasmacyte-rich meningioma involving the whole intracranial dura mater. Neurology. 2018;90(20):934–5.PubMedCrossRef Yang X, et al. Lymphoplasmacyte-rich meningioma involving the whole intracranial dura mater. Neurology. 2018;90(20):934–5.PubMedCrossRef
30.
Zurück zum Zitat Avninder S, Gupta V, Sharma KC. Lymphoplasmacyte-rich meningioma at the foramen magnum. Br J Neurosurg. 2008;22(5):702–4.PubMedCrossRef Avninder S, Gupta V, Sharma KC. Lymphoplasmacyte-rich meningioma at the foramen magnum. Br J Neurosurg. 2008;22(5):702–4.PubMedCrossRef
31.
Zurück zum Zitat Majumdar K, et al. Sphenoid wing lymphoplasmacyte-rich meningioma with occasional emperipolesis closely simulating an intracranial Rosai-Dorfman disease: a diagnostic dilemma. Clin Neuropathol. 2013;32(2):122–7.PubMedCrossRef Majumdar K, et al. Sphenoid wing lymphoplasmacyte-rich meningioma with occasional emperipolesis closely simulating an intracranial Rosai-Dorfman disease: a diagnostic dilemma. Clin Neuropathol. 2013;32(2):122–7.PubMedCrossRef
32.
Zurück zum Zitat Fukui K, et al. A rare case of dumbbell-shaped lymphoplasmacyte-rich meningioma arising at the upper cervical spinal cord. J Orthop Sci. 2021. Fukui K, et al. A rare case of dumbbell-shaped lymphoplasmacyte-rich meningioma arising at the upper cervical spinal cord. J Orthop Sci. 2021.
33.
Zurück zum Zitat Go KG, Wilmink JT, Molenaar WM. Peritumoral brain edema associated with meningiomas. Neurosurgery. 1988;23(2):175–9.PubMedCrossRef Go KG, Wilmink JT, Molenaar WM. Peritumoral brain edema associated with meningiomas. Neurosurgery. 1988;23(2):175–9.PubMedCrossRef
35.
Zurück zum Zitat Hou J, et al. Peritumoral brain edema in intracranial meningiomas: the emergence of vascular endothelial growth factor-directed therapy. Neurosurg Focus. 2013;35(6):E2.PubMedCrossRef Hou J, et al. Peritumoral brain edema in intracranial meningiomas: the emergence of vascular endothelial growth factor-directed therapy. Neurosurg Focus. 2013;35(6):E2.PubMedCrossRef
36.
Zurück zum Zitat Yoshioka H, et al. Peritumoral brain edema associated with meningioma: influence of vascular endothelial growth factor expression and vascular blood supply. Cancer. 1999;85(4):936–44.PubMedCrossRef Yoshioka H, et al. Peritumoral brain edema associated with meningioma: influence of vascular endothelial growth factor expression and vascular blood supply. Cancer. 1999;85(4):936–44.PubMedCrossRef
37.
Zurück zum Zitat Samoto K, et al. Expression of vascular endothelial growth factor and its possible relation with neovascularization in human brain tumors. Cancer Res. 1995;55(5):1189–93.PubMed Samoto K, et al. Expression of vascular endothelial growth factor and its possible relation with neovascularization in human brain tumors. Cancer Res. 1995;55(5):1189–93.PubMed
38.
Zurück zum Zitat Ding YS, et al. Expression of vascular endothelial growth factor in human meningiomas and peritumoral brain areas. Ann Clin Lab Sci. 2008;38(4):344–51.PubMed Ding YS, et al. Expression of vascular endothelial growth factor in human meningiomas and peritumoral brain areas. Ann Clin Lab Sci. 2008;38(4):344–51.PubMed
39.
Zurück zum Zitat Gilbert JJ, et al. Cerebral edema associated with meningiomas. Neurosurgery. 1983;12(6):599–605.PubMedCrossRef Gilbert JJ, et al. Cerebral edema associated with meningiomas. Neurosurgery. 1983;12(6):599–605.PubMedCrossRef
40.
Zurück zum Zitat Bitzer M, et al. Tumor-related venous obstruction and development of peritumoral brain edema in meningiomas. Neurosurgery. 1998;42(4):730–7.PubMedCrossRef Bitzer M, et al. Tumor-related venous obstruction and development of peritumoral brain edema in meningiomas. Neurosurgery. 1998;42(4):730–7.PubMedCrossRef
41.
Zurück zum Zitat Bradac GB, et al. Peritumoral edema in meningiomas A radiological and histological study. Neuroradiology. 1986;28(4):304–12.PubMedCrossRef Bradac GB, et al. Peritumoral edema in meningiomas A radiological and histological study. Neuroradiology. 1986;28(4):304–12.PubMedCrossRef
42.
Zurück zum Zitat Wang DJ, et al. Secretory meningiomas: clinical, radiological and pathological findings in 70 consecutive cases at one institution. Int J Clin Exp Pathol. 2013;6(3):358–74.PubMedPubMedCentral Wang DJ, et al. Secretory meningiomas: clinical, radiological and pathological findings in 70 consecutive cases at one institution. Int J Clin Exp Pathol. 2013;6(3):358–74.PubMedPubMedCentral
43.
Zurück zum Zitat Osawa T, et al. Factors affecting peritumoral brain edema in meningioma: special histological subtypes with prominently extensive edema. J Neurooncol. 2013;111(1):49–57.PubMedCrossRef Osawa T, et al. Factors affecting peritumoral brain edema in meningioma: special histological subtypes with prominently extensive edema. J Neurooncol. 2013;111(1):49–57.PubMedCrossRef
44.
Zurück zum Zitat Park KJ, et al. Influence of interleukin-6 on the development of peritumoral brain edema in meningiomas. J Neurosurg. 2010;112(1):73–80.PubMedCrossRef Park KJ, et al. Influence of interleukin-6 on the development of peritumoral brain edema in meningiomas. J Neurosurg. 2010;112(1):73–80.PubMedCrossRef
45.
Zurück zum Zitat Frati A, et al. Peritumoral Brain Edema in Relation to Tumor Size Is a Variable That Influences the Risk of Recurrence in Intracranial Meningiomas. Tomography. 2022;8(4):1987–96.PubMedPubMedCentralCrossRef Frati A, et al. Peritumoral Brain Edema in Relation to Tumor Size Is a Variable That Influences the Risk of Recurrence in Intracranial Meningiomas. Tomography. 2022;8(4):1987–96.PubMedPubMedCentralCrossRef
46.
Zurück zum Zitat Horten BC, Urich H, Stefoski D. Meningiomas with conspicuous plasma cell-lymphocytic components: a report of five cases. Cancer. 1979;43(1):258–64.PubMedCrossRef Horten BC, Urich H, Stefoski D. Meningiomas with conspicuous plasma cell-lymphocytic components: a report of five cases. Cancer. 1979;43(1):258–64.PubMedCrossRef
47.
Zurück zum Zitat Gi H, et al. Meningioma with hypergammaglobulinemia. Case report J Neurosurg. 1990;73(4):628–9.PubMed Gi H, et al. Meningioma with hypergammaglobulinemia. Case report J Neurosurg. 1990;73(4):628–9.PubMed
48.
Zurück zum Zitat Weidenheim KM, Campbell WG Jr, Goldman HW. Atypical monoclonal plasma cell hyperplasia of the central nervous system: precursor of plasmacytoma with evolutionary considerations. Neurosurgery. 1989;24(3):429–34.PubMedCrossRef Weidenheim KM, Campbell WG Jr, Goldman HW. Atypical monoclonal plasma cell hyperplasia of the central nervous system: precursor of plasmacytoma with evolutionary considerations. Neurosurgery. 1989;24(3):429–34.PubMedCrossRef
49.
Zurück zum Zitat Gregorios JB, Bay JW, Dudley AW Jr. Extramedullary hematopoiesis in a malignant meningioma. Neurosurgery. 1983;13(4):447–51.PubMedCrossRef Gregorios JB, Bay JW, Dudley AW Jr. Extramedullary hematopoiesis in a malignant meningioma. Neurosurgery. 1983;13(4):447–51.PubMedCrossRef
50.
Zurück zum Zitat Kepes JJ, et al. “Chordoid” meningeal tumors in young individuals with peritumoral lymphoplasmacellular infiltrates causing systemic manifestations of the Castleman syndrome A report of seven cases. Cancer. 1988;62(2):391–406.PubMedCrossRef Kepes JJ, et al. “Chordoid” meningeal tumors in young individuals with peritumoral lymphoplasmacellular infiltrates causing systemic manifestations of the Castleman syndrome A report of seven cases. Cancer. 1988;62(2):391–406.PubMedCrossRef
51.
Zurück zum Zitat Cao L, Li H. Enhancement of blurry retinal image based on non-uniform contrast stretching and intensity transfer. Med Biol Eng Comput. 2020;58(3):483–96.PubMedCrossRef Cao L, Li H. Enhancement of blurry retinal image based on non-uniform contrast stretching and intensity transfer. Med Biol Eng Comput. 2020;58(3):483–96.PubMedCrossRef
52.
Zurück zum Zitat Mehmood A, et al. A non-uniform quantization scheme for visualization of CT images. Math Biosci Eng. 2021;18(4):4311–26.PubMedCrossRef Mehmood A, et al. A non-uniform quantization scheme for visualization of CT images. Math Biosci Eng. 2021;18(4):4311–26.PubMedCrossRef
53.
Zurück zum Zitat Sundarapandian M, Kalpathi R, Manason VD. DSA image registration using non-uniform MRF model and pivotal control points. Comput Med Imaging Graph. 2013;37(4):323–36.PubMedCrossRef Sundarapandian M, Kalpathi R, Manason VD. DSA image registration using non-uniform MRF model and pivotal control points. Comput Med Imaging Graph. 2013;37(4):323–36.PubMedCrossRef
Metadaten
Titel
Epidemiology, characteristics, and prognostic factors of lymphoplasmacyte-rich meningioma: a systematic literature review
verfasst von
Xiaoxi Zhu
Yanhua Liu
Weiwei Guo
Qi Liang
Chengliang Pan
Bin Tan
Ying Yu
Publikationsdatum
01.12.2024
Verlag
BioMed Central
Erschienen in
BMC Cancer / Ausgabe 1/2024
Elektronische ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-023-11811-4

Weitere Artikel der Ausgabe 1/2024

BMC Cancer 1/2024 Zur Ausgabe

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

13.05.2024 Pankreaskarzinom Nachrichten

Gerade bei aggressiven Malignomen wie dem duktalen Adenokarzinom des Pankreas könnte Früherkennung die Therapiechancen verbessern. Noch jedoch klafft hier eine Lücke. Ein Studienteam hat einen Weg gesucht, sie zu schließen.

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

12.05.2024 Prostatakarzinom Nachrichten

Ein hoher Anteil pflanzlicher Nahrung trägt möglicherweise dazu bei, das Progressionsrisiko von Männern mit Prostatakarzinomen zu senken. In einer US-Studie war das Risiko bei ausgeprägter pflanzlicher Ernährung in etwa halbiert.

Alter verschlechtert Prognose bei Endometriumkarzinom

11.05.2024 Endometriumkarzinom Nachrichten

Ein höheres Alter bei der Diagnose eines Endometriumkarzinoms ist mit aggressiveren Tumorcharakteristika assoziiert, scheint aber auch unabhängig von bekannten Risikofaktoren die Prognose der Erkrankung zu verschlimmern.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.